The randomised controlled trial (RCT) is just over 50 years old as a technology for medical research.' During that time it has risen to become the so-called 'gold standard' for investigations in the health field, well beyond its original application for the evaluation of drug treatments. As it has spread to health services research, the RCT's validity has been increasingly questioned, particularly by social scientists. However, it has continued to draw immense prestige from its success in the rapid advance of effective medical therapies since World War II. Ironically, the advance of genomic research now suggests that the basic assumptions of the RCT may be unsustainable. The methodological problems identified by social scientists now seem applicable with equal force to its validity as a means of evaluating biological systems.
The heyday of the RCT coincided with what industrial sociologists have called the era of 'Fordism', Fordism is a mode of production that aims to cater for the average taste of populations at the lowest possible cost through realising the economies of scale associated with very large production runs of highly standardised products. It is, of course, epitomised by the Model T Ford in the 1920s and the eponymous designer's dictum that you could buy it in any colour you wanted as long as it was black. However, the apogee of Fordism was reached after World War II when the experience of mass production in wartime was applied to the buoyant civilian markets of the postwar economic boom, which it further reinforced.
The RCT is a Fordist mode of investigation, closely allied to the rise of one of the great Fordist industries, pharmaceuticals. In a given population, randomly divided, it charts the average response of each group to an intervention and a control or placebo. The intervention that produces the stronger average therapeutic response, and fewer average adverse effects, can be rolled out across the entire population. The producers of this intervention can replicate it on an enormous scale and reap the associated productive benefits: the pharmaceutical industry has been one of the most profitable sectors of the industrial economies over the last half century. Its success has encouraged emulation in other areas of health care, most notably by the Cochrane Collaboration in their attempt to sweep all known RCTs into a mega-Fordist project aimed at the standardisation of clinical practice and health service delivery according to the 'best' evidence of effectiveness. (There is, of course, a certain irony in naming this movement after Archie Cochrane who was quite clear about the methodological limits of the randomised trial.)
The obituaries for Fordism have long been written in other areas of industrial production. Populations do not have uniform tastes and needs, and production aimed only at satisfying the average consumer is only averagely satisfying. Fordism was always vulnerable to niche production, targeted more precisely at specific groups or individuals, provided that the costs of identifying those groups and producing for them could be made low enough. Modern market research and computerised production technologies now allow a range of units to be combined in individually sensitive ways at a cost comparable to that of traditional assembly-line production. Some of the great companies of the postwar period were eventually brought to their knees by their failure to recognise this challenge. Who would have predicted that the mighty IBM would have lost out to a collection of faster-moving entrepreneurs, culminating in the current Dell approach which can build each PC to an individual specification at a cost competitive with those manufacturers who still sell prepackaged machines?
The RCT worked for as long as its users could make the same Fordist assumptions about the homogeneity of populations. Although there might be some variance in response, a patient treated with a drug found, on average, to be superior in a population to the others available would be more likely than not to get a superior result. The generalisation from data on populations to predictions about individuals has long been suspect in social science, under the label of the 'ecological fallacy'. However, it has only come to be recognised as a practical problem for biology with the increasing understanding of the human genome. Biologically, it seems, our constitutions vary at least as much as our consumer tastes and needs.
Randomisation conceals this variation in pursuit of the average effect. However, it is precisely this variation, and sensitivity to it, that is the key to finding the most effective treatments for particular individuals. The industrial response to this challenge, as embodied in pharmacogenetics, is to attempt to standardise populations for their genomes before randomising them for lnterventions.f In this new paradigm it is hoped that human genomes are sufficiently uniform for trials to be able to identify drugs that will suit about 30% of a current market, with some hope of recovering research, development and approval costs. This will fragment markets, but the industry hopes that, in time, new drugs can be developed that will be more narrowly targeted as a unique therapy for particular subgroups and will sell, preferably at a premium, to all of that subpopulation. However, preselecting groups on the basis of their genotype before entry into randomised trials poses major dilemmas for regulatory agencies. If drugs are approved on this basis, how can their use in other segments of the population, which have different genomes, be controlled?
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The promise of pharmacogenetics may prove to be a Utopian illusion. Present thinking seems to be putting increasing stress on the diversity rather than on the uniformity of the human genome, particularly in the extent to which genes interact with each other rather than operating in isolation. The single gene controlling a specific process is likely to be the exception rather than the rule. The current strategy of the pharmaceutical industry, therefore, might be vulnerable to any competitor who can crack the problem of designing and manufacturing therapies for small groups or individuals. In the process, the RCT could fall by the wayside in favour of laboratory-based assessments that examine the response of any given individual to a particular intervention.
We have barely begun to appreciate the ways in which the health care and drug industries will change over the next half century. Clearly, pharmaceutical companies are powerful actors with the ability to buy up competing technologies and to pressure regulators to raise market entry costs for new entities and novel product development strategies. Large parts of the medical scientific establishment have huge vested interests in the RCT. But analysts of the computing industry would have said the same about the dominance of IBM in 1970. As Schumpeter noted, capitalism advances by creative destruction.f It would be unwise to bet against some of today's pharmaceutical giants being eclipsed by new firms that solve the problem of more precisely targeting 68 J Health Serv Res Policy Vol 5 No 2 April 2000 therapy at small groups and individuals. In the process, we might all be liberated from the notion that RCTs will produce a 'best buy' list in medical practice. 'One-size fits all' means that it fits no-one very well. A more appropriate research and policy agenda for the next half century is likely to concentrate on respecting, supporting and improving the clinical skills of health professionals rather than subordinating them to practise algorithms. The Post-Fordist consumer is unlikely to settle for less.
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